Advances in immunotherapeutics in pancreatic ductal adenocarcinoma
T Chouari, FS La Costa, N Merali, MD Jessel… - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective
TJ Herzog, I Vergote, LG Gomella, T Milenkova… - European Journal of …, 2023 - Elsevier
Poly (ADP-ribose) polymerase inhibitors (PARPis) have demonstrated clinical activity in
patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic …
patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic …
Recent progress in the development of nanomaterials targeting multiple cancer metabolic pathways: a review of mechanistic approaches for cancer treatment
L Zhang, BZ Zhai, YJ Wu, Y Wang - Drug Delivery, 2023 - Taylor & Francis
Cancer is a very heterogeneous disease, and uncontrolled cell division is the main
characteristic of cancer. Cancerous cells need a high nutrition intake to enable aberrant …
characteristic of cancer. Cancerous cells need a high nutrition intake to enable aberrant …
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
HC Kung, J Yu - MedComm, 2023 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …
Pancreatic cancer with mutation in BRCA1/2, MLH1, and APC genes: phenotype correlation and detection of a novel germline BRCA2 mutation
MT Vietri, G D'Elia, G Caliendo, L Albanese… - Genes, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer death
worldwide; most of cases are sporadic, however about 5% to 10% report a hereditary …
worldwide; most of cases are sporadic, however about 5% to 10% report a hereditary …
Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy
At least 5% of cancer diagnoses are attributed to a causal pathogenic or likely pathogenic
germline genetic variant (hereditary cancer syndrome—HCS). These individuals are …
germline genetic variant (hereditary cancer syndrome—HCS). These individuals are …
Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
M Sekine, K Nishino, T Enomoto - Genes, 2021 - mdpi.com
Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2
genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline …
genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline …
Autophagy: a key player in pancreatic cancer progression and a potential drug target
J Gillson, YS Abd El-Aziz, LYW Leck, PJ Jansson… - Cancers, 2022 - mdpi.com
Simple Summary With the mortality rate of pancreatic cancer predicted to rise over the
coming years, it is essential that effective treatment strategies are developed as soon as …
coming years, it is essential that effective treatment strategies are developed as soon as …
[HTML][HTML] BRCA2 gene mutation in cancer
C Xie, J Luo, Y He, L Jiang, L Zhong, Y Shi - Medicine, 2022 - journals.lww.com
Breast cancer susceptibility gene 2 (BRCA2) is the main gene associated with hereditary
breast cancers. However, a mutation in BRCA2 has also been found in other tumors, such …
breast cancers. However, a mutation in BRCA2 has also been found in other tumors, such …
[HTML][HTML] Progress on diagnostic and prognostic markers of pancreatic cancer
H Yang, W Li, L Ren, Y Yang, Y Zhang, B Ge… - Oncology …, 2023 - ncbi.nlm.nih.gov
Pancreatic cancer is a malignant disease characterized by low survival and high recurrence
rate, whose patients are mostly at the stage of locally advanced or metastatic disease when …
rate, whose patients are mostly at the stage of locally advanced or metastatic disease when …